Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma

Abstract

The p53 signaling pathway works as a potent barrier to tumor progression. Two single nucleotide polymorphisms (SNPs) in the gene loci of p53 pathway, p53 codon 72 Arg72Pro and MDM2 SNP309 (T>G), have been shown to cause perturbation of p53 function, but the effect of the two SNPs on the risk of hepatocellular carcinoma (HCC) remains inconsistent. This study investigated the influence of combined p53 Arg72Pro and MDM2 SNP309 on the risk of developing HCC in patients with chronic hepatitis B virus infection, and evaluated the significance of the two combined SNPs on patient prognosis. In total, 350 HCC patients, 230 non-HCC patients, and 96 healthy controls were genotyped for the p53 Arg72Pro and MDM2 SNP309. The combined p53 Pro/Pro and MDM2 G/G genotype was significantly associated with HCC risk (P= 0.047). Multivariate analysis indicated that combined p53 Pro/Pro and MDM2 G/G genotype was an independent factor affecting recurrence and survival (P<0.05). Patients with combined p53 Pro/Pro and MDM2 G/G genotypes had a poorer prognosis than other genotypes, P<0.01 for both disease-free survival (DFS) and overall survival (OS). DFS and OS rates also differed significantly between Barcelona Clinic Liver Cancer (BCLC) stage A patients with combined p53 Pro/Pro and MDM2 G/G and other genotypes (P<0.05). Thus, the combined p53 Pro/Pro and MDM2 G/G genotype is associated with increased risk of developing HCC and is an independent adverse prognostic indicator in early stage HCC.

Keywords

hepatocellular carcinoma / p53 / MDM2 / single nucleotide polymorphisms / prognosis

References

[1] Anzola, M. (2004). Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11, 383-393 .10.1111/j.1365-2893.2004.00521.x
[2] Baptiste, N., Friedlander, P., Chen, X.B., and Prives, C. (2002). The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21, 9-21 .10.1038/sj.onc.1205015
[3] Blonski, W., Kotlyar, D.S., and Forde, K.A. (2010). Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 16, 3603-3615 .10.3748/wjg.v16.i29.3603
[4] Boersma, B.J., Howe, T.M., Goodman, J.E., Yfantis, H.G., Lee, D.H., Chanock, S.J., and Ambs, S. (2006). Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98, 911-919 .10.1093/jnci/djj245
[5] Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., . (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 .10.1016/j.cell.2004.11.022
[6] Brechot, C. (2004). Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127, S56-61 .10.1053/j.gastro.2004.09.016
[7] Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., Christensen, E., Pagliaro, L., Colombo, M., Rodes, J., . (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver . J Hepat 35, 421-430 .10.1016/S0168-8278(01)00130-1
[8] Buendia, M.A. (2000). Genetics of hepatocellular carcinoma. Semin Cancer Biol 10, 185-200 .10.1006/scbi.2000.0319
[9] Cescon, D.W., Bradbury, P.A., Asomaning, K., Hopkins, J., Zhai, R., Zhou, W., Wang, Z., Kulke, M., Su, L., Ma, C., . (2009). p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res 15, 3103-3109 .10.1158/1078-0432.CCR-08-3120
[10] Clifford, R.J., Zhang, J., Meerzaman, D.M., Lyu, M.-S., Hu, Y., Cultraro, C.M., Finney, R.P., Kelley, J.M., Efroni, S., Greenblum, S.I., . (2010). Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 52, 2034-2043 .10.1002/hep.23943
[11] Dharel, N., Kato, N., Muroyama, R., Moriyama, M., Shao, R.X., Kawabe, T., and Omata, M. (2006). MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12, 4867-4871 .10.1158/1078-0432.CCR-06-0111
[12] Dumont, P., Leu, J.I.J., Della Pietra, A.C., George, D.L., and Murphy, M. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365 .10.1038/ng1093
[13] Edamoto, Y., Hara, A., Biernat, W., Terracciano, L., Cathomas, G., Riehle, H.M., Matsuda, M., Fujii, H., Scoazec, J.Y., and Ohgaki, H. (2003). Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer Suppl 106, 334-341 .10.1002/ijc.11254
[14] Edmondson, H.A., and Steiner, P.E. (1954). Primary Carcinoma of the Liver- a Study of 100 Cases among 48,900 Necropsies. Cancer 7, 462-503 .10.1002/1097-0142(195405)7:3&lt;462::AID-CNCR2820070308&gt;3.0.CO;2-E
[15] El-Serag, H.B., and Rudolph, K.L. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 .10.1053/j.gastro.2007.04.061
[16] Grochola, L.F., Zeron-Medina, J., Meriaux, S., and Bond, G.L. (2010). Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol 2, a001032.10.1101/cshperspect.a001032
[17] Han, J.Y., Lee, G.K., Jang, D.H., Lee, S.Y., and Lee, J.S. (2008). Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113, 799-807 .10.1002/cncr.23668
[18] Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 .10.1038/387296a0
[19] Hino, O., Tabata, S., and Hotta, Y. (1991). Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A 88, 9248-9252 .10.1073/pnas.88.20.9248
[20] Hirata, H., Hinoda, Y., Kikuno, N., Kawamoto, K., Suehiro, Y., Tanaka, Y., and Dahiya, R. (2007). MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 13, 4123-4129 .10.1158/1078-0432.CCR-07-0609
[21] Horikawa, Y., Nadaoka, J., Saito, M., Kumazawa, T., Inoue, T., Yuasa, T., Tsuchiya, N., Nishiyama, H., Ogawa, O., and Habuchi, T. (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 20, 49-55 .
[22] Kao, J.H., Chen, P.J., Lai, M.Y., and Chen, D.S. (2000). Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118, 554-559 .10.1016/S0016-5085(00)70261-7
[23] Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303 .10.1038/387299a0
[24] Lai, E.C., and Lau, W.Y. (2005). The continuing challenge of hepatic cancer in Asia. Surgeon 3, 210-215 .10.1016/S1479-666X(05)80043-5
[25] Leu, J.D., Lin, I.F., Sun, Y.F., Chen, S.M., Liu, C.C., and Lee, Y.J. (2009). Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 15, 5592-5597 .10.3748/wjg.15.5592
[26] Lin, C.L., and Kao, J.H. (2008). Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 15, 137-145 .10.1007/s11373-007-9225-8
[27] Nault, J.C., and Zucman-Rossi, J. (2011). Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31, 173-187 .10.1055/s-0031-1276646
[28] Neuveut, C., Wei, Y., and Buendia, M.A. (2010). Mechanisms of HBV-related hepatocarcinogenesis. J Hepat 52, 594-604 .10.1016/j.jhep.2009.10.033
[29] Parkin, D.M. (2001). Global cancer statistics in the year 2000. Lancet Oncol 2, 533-543 .10.1016/S1470-2045(01)00486-7
[30] Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., and Olivier, M. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutat 28, 622-629 .10.1002/humu.20495
[31] Pim, D., and Banks, L. (2004). p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108, 196-199 .10.1002/ijc.11548
[32] Puisieux, A., Ji, J., Guillot, C., Legros, Y., Soussi, T., Isselbacher, K., and Ozturk, M. (1995). p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci U S A 92, 1342-1346 .10.1073/pnas.92.5.1342
[33] Sherman, M. (2005). Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25, 143-154 .10.1055/s-2005-871194
[34] Silini, E., Bottelli, R., Asti, M., Bruno, S., Candusso, M.E., Brambilla, S., Bono, F., Iamoni, G., Tinelli, C., Mondelli, M.U., . (1996). Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 111, 199-205 .10.1053/gast.1996.v111.pm8698200
[35] Talseth, B.A., Meldrum, C., Suchy, J., Kurzawski, G., Lubinski, J., and Scott, R.J. (2007). MDM2 SNP309 T&gt;G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120, 563-565 .10.1002/ijc.22339
[36] Toffoli, G., Biason, P., Russo, A., De Mattia, E., Cecchin, E., Hattinger, C.M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., . (2009). Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 15, 3550-3556 .10.1158/1078-0432.CCR-08-2249
[37] Xiao, M., Zhang, L., Zhu, X., Huang, J., Jiang, H., Hu, S., and Liu, Y. (2010). Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC cancer 10, 147.Yang, L.Y., Fang, F., Ou, D.P., Wu, W., Zeng, Z.J., and Wu, F. (2009). Solitary large hepatocellular carcinoma a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 249, 118-123 .10.1186/1471-2407-10-147
[38] Yang, L.Y., Fang, F., Ou, D.P., Wu, W., Zeng, Z.J., and Wu, F. (2009). Solitary large hepatocellular carcinoma a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 249, 118–123 .10.1097/SLA.0b013e3181904988
[39] Yoon, Y.J., Chang, H.Y., Ahn, S.H., Kim, J.K., Park, Y.K., Kang, D.R., Park, J.Y., Myoung, S.M., Kim do, Y., Chon, C.Y., . (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29, 1192-1196 .10.1093/carcin/bgn090
[40] Yuen, M.F., Hou, J.L., Chutaputti, A., and Asia Pacific Working Party on Prevention of Hepatocellular, C. (2009). Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepat 24, 346-353 .10.1111/j.1440-1746.2009.05784.x
[41] Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T., Wang, Y., and Lin, D. (2006). Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Human Mutat 27, 110- 117.10.1002/humu.20277